Serum advanced glycation end products are associated with insulin resistance in male nondiabetic patients with obstructive sleep apnea

Sleep and Breathing

Volumn 19, Issue 3, 2015, Pages 827-833

  Xu, Ji xiong ^a   Cai, Wei ^a   Sun, Jian fang ^a   Liao, Wei jian ^a   Liu, Ying ^a   Xiao, Jun ren ^a   Zhu, Ling yan ^a   Liu, Jian ying ^a   Zhang, Wei ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Diabetes; Insulin resistance; Obstructive sleep apnea

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; OXYGEN;

ADULT; APNEA HYPOPNEA INDEX; ARTICLE; BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SLEEP DISORDERED BREATHING; WAIST CIRCUMFERENCE; BLOOD; FEMALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYSOMNOGRAPHY; SLEEP STAGE; STATISTICS;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OXYGEN; POLYSOMNOGRAPHY; SLEEP APNEA, OBSTRUCTIVE; SLEEP STAGES; STATISTICS AS TOPIC;

EID: 84940963643     PISSN: 15209512     EISSN: 15221709     Source Type: Journal    
DOI: 10.1007/s11325-014-1100-z     Document Type: Article

References (30)

1. Tasali E, Mokhlesi B, Van Cauter E (2008) Obstructive sleep apnea and type 2 diabetes: interacting epidemics. Chest 133:496–506. doi:10.1378/chest. 07-0828
2. Aurora RN, Punjabi NM (2013) Obstructive sleep apnoea and type 2 diabetes mellitus: a bidirectional association. Lancet Respir Med 1:329–338. doi:10.1016/S2213-2600(13)70039-0
3. Pamidi S, Wroblewski K, Broussard J, Day A, Hanlon E, Abraham V, Tasali E (2012) Obstructive sleep apnea in young lean men: impact on insulin sensitivity and secretion. Diabetes Care 35:2384–2389. doi:10.2337/dc12-0841
4. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW (1991) Formation of pentosidine during nonenzymatic browning of proteins by glucose. identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266:11654–11660
5. Ramasamy R, Yan SF, Schmidt AM (2012) Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids 42:1151–1161. doi:10.1007/s00726-010-0773-2
6. Xu Y, Toure F, Qu W, Lin L, Song F, Shen X, Rosario R, Garcia J, Schmidt AM, Yan SF (2010) Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J Biol Chem 285:23233–23240. doi:10.1074/jbc.M110.117457
7. Kimoff RJ, Hamid Q, Divangahi M, Hussain S, Bao W, Naor N, Payne RJ, Ariyarajah A, MulrainK PBJ (2011) Increased upper airway cytokines and oxidative stress in severe obstructive sleep apnoea. Eur Respir J 38:89–97. doi:10.1183/09031936.00048610
8. Tan KC, Chow WS, Lam JC, Lam B, Bucala R, Betteridge J, Ip MS (2006) Advanced glycation endproducts in nondiabetic patients with obstructive sleep apnea. Sleep 29(3):329–333
9. Lam JC, Tan KC, Lai AY, Lam DC, Ip MS (2012) Increased serum levels of advanced glycation end-products is associated with severity of sleep disordered breathing but not insulin sensitivity in non-diabetic men with obstructive sleep apnoea. Sleep Med 13:15–20. doi:10.1016/j.sleep.2011.07.015
10. Celec P, Hodosy J, Behuliak M, Pálffy R, Gardlík R, Halčák L, Mucska I (2012) Oxidative and carbonyl stress in patients with obstructive sleep apnea treated with continuous positive airway pressure. Sleep Breath 16:393–398. doi:10.1007/s11325-011-0510-4
11. Yan SF, Ramasamy R, Schmidt AM (2010) The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 106:842–853. doi:10.1161/CIRCRESAHA.109.212217
12. Riboulet-Chavey A, Pierron A, Durand I, Murdaca J, Giudicelli J, Van Obberghen E (2006) Methylglyoxal impairs the insulin signaling pathways independently of the formation of intracellular reactive oxygen species. Diabetes 55:1289–1299
13. Unoki H, Bujo H, Yamagishi S, Takeuchi M, Imaizumi T, Saito Y (2007) Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen s pecies in adipocytes. Diabetes Res Clin Pract 76:236–244
14. Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H (2012) Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A 109:15888–15893
15. Mark AB, Poulsen MW, Andersen S, Andersen JM, Bak MJ, Ritz C, Holst JJ, Nielsen J, de Courten B, Dragsted LO, Bügel SG (2014) Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care 37:88–95. doi:10.2337/dc13-0842
16. Uribarri J1, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, Zhu L, Striker GE, Vlassara H (2011) Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 34:1610–1616. doi:10.2337/dc11-0091
17. Tan KC, Shiu SW, Wong Y, Tam X (2011) Serum advanced glycation end products (AGEs) are associated with insulin resistance. Diabetes Metab Res Rev 27:488–492. doi:10.1002/dmrr.1188
18. Tahara N, Yamagishi S, Matsui T, Takeuchi M, Nitta Y, Kodama N, Mizoguchi M, Imaizumi T (2012) Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther 30:42–48. doi:10.1111/j.1755-5922.2010.00177.x
19. Hamilton MT, Hamilton DG, Zderic TW (2007) Role of low energy expenditure and sitting in obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease. Diabetes 56:2655–2667
20. Stöhr R, Federici M (2013) Insulin resistance and atherosclerosis: convergence between metabolic pathways and inflammatory nodes. Biochem J 454:1–11. doi:10.1042/BJ20130121
21. Bohlender JM, Franke S, Stein G, Wolf G (2005) Advanced glycation end products and the kidney. Am J Renal Physiol 289:F645–F659
22. Tasali E, Leproult R, Ehrmann DA, Cauter EV (2008) Slow-wave sleep and the risk of type 2 diabetes in humans. PNAS 105:1044–1049
23. Shi YK, Chen JX, Huang Y, Li AY (2014) Serum S100A12 levels are associated with the presence and severity of obstructive sleep apnea syndrome in male patients. Sleep Breath 18:269–274. doi:10.1007/s11325-013-0876-6
24. Miele C, Riboulet A, Maitan MA, Oriente F, Romano C, Formisano P, Giudicelli J, Beguinot F, Van Obberghen E (2003) Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism. J Biol Chem 278:47376–47387
25. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R (2002) Advanced glycation end products activate endothelium through signal-transduction receptor rage: a mechanism for amplification of inflammatory responses. Circulation 105:816–822
26. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS (2002) A central role for JNK in obesity and insulin resistance. Nature 420:333–336
27. Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H (2005) Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 54:2314–2319
28. Hofmann SM, Dong HJ, Li Z, Cai W, Altomonte J, Thung SN, Zeng F, Fisher EA, Vlassara H (2002) Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 51:2082–2089
29. Vlassara H1, Cai W, Goodman S, Pyzik R, Yong A, Chen X, Zhu L, Neade T, Beeri M, Silverman JM, Ferrucci L, Tansman L, Striker GE, Uribarri J (2009) Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 94:4483–4491. doi:10.1210/jc.2009-0089
30. Takeuchi M, Yamagishi S (2008) Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer’s disease. Curr Pharm Des 14:973–978